| scholarly article | Q13442814 |
| P50 | author | Gabriella Moroni | Q46463588 |
| P2093 | author name string | Claudio Ponticelli | |
| Richard J Glassock | |||
| P2860 | cites work | Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus | Q24202505 |
| Membranoproliferative glomerulonephritis--a new look at an old entity | Q28262402 | ||
| Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes | Q29547541 | ||
| Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data | Q31004418 | ||
| Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy | Q33251433 | ||
| Thrombotic microangiopathy early after kidney transplantation: hemolytic uremic syndrome or vascular rejection? | Q33332843 | ||
| De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy | Q33346269 | ||
| Thrombotic microangiopathy after renal transplantation in the United States | Q33357327 | ||
| Thrombotic microangiopathy after kidney transplantation | Q33372586 | ||
| De novo thrombotic microangiopathy. An underrated complication of renal transplantation | Q33375722 | ||
| Post-renal transplant hemolytic uremic syndrome following combination therapy with tacrolimus and everolimus | Q33377083 | ||
| Recurrent and de novo renal disease after kidney transplantation with or without cyclosporine A. | Q33388694 | ||
| De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection | Q33390970 | ||
| A case of progressive thrombotic microangiopathy after ABO-incompatible renal transplantation | Q33395562 | ||
| Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation--a case report | Q33395870 | ||
| De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival | Q33403602 | ||
| Induction of B7-1 in podocytes is associated with nephrotic syndrome | Q33785088 | ||
| Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis | Q33872298 | ||
| Antineutrophil cytoplasmic antibodies (ANCA) and systemic vasculitis: update of assays, immunopathogenesis, controversies, and report of a novel de novo ANCA-associated vasculitis after kidney transplantation | Q33915352 | ||
| Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis | Q34088479 | ||
| Outcomes of male patients with Alport syndrome undergoing renal replacement therapy. | Q34301017 | ||
| Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies | Q34503063 | ||
| Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease | Q34624477 | ||
| Incidence of latent mesangial IgA deposition in renal allograft donors in Japan | Q34648471 | ||
| Circulating Permeability Factors in Idiopathic Nephrotic Syndrome and Focal Segmental Glomerulosclerosis | Q34660324 | ||
| Sirolimus is associated with new-onset diabetes in kidney transplant recipients. | Q34767143 | ||
| De novo minimal change disease associated with reversible post-transplant nephrotic syndrome. A report of five cases and review of literature | Q34842550 | ||
| Alport's syndrome, Goodpasture's syndrome, and type IV collagen. | Q35157829 | ||
| Cyclosporine nephrotoxicity | Q35299740 | ||
| Acute post-bacterial glomerulonephritis in renal transplant patients: description of three cases and review of the literature | Q35608776 | ||
| Tacrolimus and posttransplant diabetes mellitus in renal transplantation | Q36154176 | ||
| Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes | Q36549321 | ||
| Histopathology of diabetic nephropathy | Q36785588 | ||
| Parvovirus B19 and the kidney | Q36910665 | ||
| Recurrent glomerulonephritis after renal transplantation: an unsolved problem | Q37084056 | ||
| Probability, predictors, and prognosis of posttransplantation glomerulonephritis | Q37146427 | ||
| Cyclosporine induces endothelial cell release of complement-activating microparticles | Q37260192 | ||
| Abatacept in B7-1-positive proteinuric kidney disease | Q37633142 | ||
| De novo membranous nephropathy (MN) in kidney allografts. A peculiar form of alloimmune disease? | Q38036393 | ||
| Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation | Q38127967 | ||
| De novo membranous glomerulonephropathy in renal allografts: a report of ten cases and review of the literature | Q38670888 | ||
| Focal segmental glomerulosclerosis in renal allografts with chronic nephropathy: implications for graft survival | Q40794386 | ||
| Collapsing glomerulopathy in renal allograft biopsies: A study of nine cases | Q42748427 | ||
| Glomerular disease during HCV infection in renal transplantation | Q42980199 | ||
| De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. | Q43037104 | ||
| Impact of glucose metabolism abnormalities on histopathological changes in kidney transplant protocol biopsies | Q43244363 | ||
| Focal and segmental glomerulosclerosis in renal allograft recipients: a clinico-pathologic study of 37 cases. | Q44058643 | ||
| Molecular identification of SV40 infection in human subjects and possible association with kidney disease | Q44193216 | ||
| Postinfectious glomerulonephritis in renal allograft recipients | Q44586512 | ||
| Outcome of Plasma Exchange Therapy in Thrombotic Microangiopathy After Renal Transplantation | Q44596912 | ||
| Prevalence of cryoglobulinemia and autoimmunity markers in renal-transplant patients. | Q44827760 | ||
| Sirolimus interacts with pathways essential for podocyte integrity | Q45151652 | ||
| IgA nephropathy with crescents in kidney transplant recipients | Q45254612 | ||
| Hepatitis C virus infection and de novo glomerular lesions in renal allografts | Q45731872 | ||
| Recurent and de novo membranous glomerulopathy after kidney transplantation | Q46070757 | ||
| Late de novo minimal change disease in a renal allograft | Q46112001 | ||
| Combined angiotensin inhibition for the treatment of diabetic nephropathy | Q46129784 | ||
| Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial | Q46155747 | ||
| Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin | Q46253287 | ||
| Latent IgA deposition from donor kidney is the major risk factor for recurrent IgA nephropathy in renal transplantation | Q46545911 | ||
| Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys | Q46702750 | ||
| Sirolimus use and de novo minimal change nephropathy following renal transplantation. | Q46868420 | ||
| Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? | Q50905310 | ||
| Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. | Q50921907 | ||
| Two cases of ANCA-associated vasculitis in post-transplant kidney: relapse and de novo. | Q51626851 | ||
| High affinity of anti-GBM antibodies from Goodpasture and transplanted Alport patients to alpha3(IV)NC1 collagen. | Q54045227 | ||
| Executive summary: standards of medical care in diabetes--2009 | Q56481478 | ||
| De novo fibrillary glomerulopathy in the renal allograft of a patient with systemic lupus erythematosus | Q64360722 | ||
| Diabetes mellitus after renal transplantation in the cyclosporine era--an analysis of risk factors | Q68196129 | ||
| De novo immunotactoid glomerulopathy of the renal allograft: possible association with cytomegalovirus infection | Q72042776 | ||
| Membranous glomerulonephritis (MGN) in transplanted kidneys: morphologic investigation on 256 renal allografts | Q72868440 | ||
| De novo ANCA-associated vasculitis occurring 14 years after kidney transplantation | Q73487134 | ||
| De novo collapsing glomerulopathy in renal allografts | Q74593302 | ||
| De novo minimal change disease | Q77308861 | ||
| Cyclosporine-associated thrombotic microangiopathy in renal allografts | Q77829502 | ||
| Renal transplant in patients with Alport's syndrome | Q77838570 | ||
| Acute cytomegalovirus infection complicated by collapsing glomerulopathy | Q78656079 | ||
| Recurrent and de novo diabetic nephropathy in renal allografts | Q78836574 | ||
| The fate of glomerular mesangial IgA deposition in the donated kidney after allograft transplantation | Q80520879 | ||
| High sirolimus levels may induce focal segmental glomerulosclerosis de novo | Q80797353 | ||
| Patterns of IgG subclass deposits in membranous glomerulonephritis in renal allografts | Q82978512 | ||
| Collapsing and non-collapsing focal segmental glomerulosclerosis in kidney transplants | Q83356461 | ||
| De novo minimal change disease after ABO-incompatible kidney transplantation | Q84498177 | ||
| Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab | Q85075727 | ||
| Case report: Eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant | Q85570146 | ||
| Angiotensin antibodies and focal segmental glomerulosclerosis | Q86290946 | ||
| Phospholipase A2 receptor (PLA2R) staining is useful in the determination of de novo versus recurrent membranous glomerulopathy | Q86439847 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1479-1487 | |
| P577 | publication date | 2014-04-03 | |
| P1433 | published in | Clinical Journal of the American Society of Nephrology | Q15757929 |
| P1476 | title | De novo glomerular diseases after renal transplantation | |
| P478 | volume | 9 |
| Q90170878 | Crescentic IgA nephropathy along with simultaneous cellular and antibody-mediated rejection in a kidney transplant leading to rapid allograft failure |
| Q38843499 | Current status of pediatric renal transplant pathology |
| Q42236892 | De Novo Focal Segmental Glomerulosclerosis in Renal Allograft-Histological Presentation and Clinical Correlation: Single Centre Experience |
| Q47172094 | De novo glomerular diseases after renal transplantation: How is it different from recurrent glomerular diseases? |
| Q91942355 | De novo minimal change disease in the renal allograft |
| Q93064469 | De novo pauci-immune glomerulonephritis in renal allografts |
| Q90705302 | Development of Focal Segmental Glomerulosclerosis and Thrombotic Microangiopathy in a Liver Transplant Patient on Sorafenib for Hepatocellular Carcinoma: A Case Report |
| Q57489220 | Early Focal Segmental Glomerulosclerosis as a Cause of Delayed Graft Function With Combined Acute Antibody Rejection: A Case Report |
| Q30238652 | Hepatitis C and kidney disease: A narrative review |
| Q26746638 | Infection-Related Focal Segmental Glomerulosclerosis in Children |
| Q92263443 | Late-Onset De Novo Minimal Change Disease Presenting With Nephrotic Range Proteinuria More Than 1 Year After Combined Heart-Kidney Transplant: A Case Report |
| Q40441782 | Outcomes of kidney transplantation in Alport syndrome compared with other forms of renal disease. |
| Q38244353 | Permeability factors in focal and segmental glomerulosclerosis |
| Q64091619 | Post-Streptococcal Glomerulonephritis in Two Patients Following Deceased Donor Kidney Transplant |
| Q38760741 | Primary Membranous Nephropathy |
| Q93047764 | Recurrent and de novo Glomerulonephritis After Kidney Transplantation |
| Q98205074 | Single-nucleotide polymorphism rs4664308 in PLA2R1 gene is associated with the risk of idiopathic membranous nephropathy: a meta-analysis |
| Q38922365 | Targeting mTOR Signaling Can Prevent the Progression of FSGS. |
| Q49338521 | Thin Glomerular Basement Membrane in a Kidney Transplant of an Alport's Syndrome Patient: A Case Report |
Search more.